Format

Send to

Choose Destination
Basic Clin Pharmacol Toxicol. 2019 Jul;125(1):3-7. doi: 10.1111/bcpt.13201. Epub 2019 Mar 12.

Myricetin inhibits panel of kinases implicated in tumorigenesis.

Author information

1
Cell Culture Laboratory, Postgraduate Program in Biotechnology, University of Taquari Valley (Univates), Lajeado, Brazil.
2
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Tübingen, Tübingen, Germany.

Abstract

Myricetin is a flavonoid with several biological properties, including antioxidant and anti-inflammatory features. Its protective effect in chronic diseases may occur through the inhibition of protein kinases that trigger inflammation and carcinogenesis pathways. Considering the influence of kinases on such pathological disorders, it is crucial to study compounds that inhibit these proteins. This study aims to evaluate the inhibitory potential of 14 flavonoids on TNF-α release in human whole blood as well as the inhibitory potential of myricetin towards kinases involved in tumorigenesis. Our results showed that, out of all flavonoids, myricetin had the highest inhibitory effect on TNF-α level. In addition, myricetin showed potential as a multi-anti-kinase compound, reducing the activity of 7 kinases by >70% and of 9 kinases by >90%. Together these data demonstrate the great inhibitory activity of myricetin on tumorigenic kinases and potential for the development of new therapeutics.

KEYWORDS:

TNF-α; cancer; flavonoid; kinase; myricetin

PMID:
30624861
DOI:
10.1111/bcpt.13201

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center